{"id":872707,"date":"2025-08-07T09:05:29","date_gmt":"2025-08-07T13:05:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/"},"modified":"2025-08-07T09:05:29","modified_gmt":"2025-08-07T13:05:29","slug":"neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/","title":{"rendered":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CALABASAS, Calif., Aug.  07, 2025  (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi\u2013Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company\u2019s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial.<\/p>\n<ul type=\"disc\">\n<li>$400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOnc\u2019s Principal Investigator (PI), with Dr. Axel H. Sch\u00f6nthal leading the academic research effort at USC\u2019s Glioma Research Group.<\/li>\n<li>$2.1 Million Phase 2 STTR Grant (2R42CA246902-02): Focused on expanding NEO212\u2019s clinical development into newly diagnosed gliomas, reinforcing the therapeutic\u2019s broad oncologic potential. Dr. Chen is the PI for NeOnc, with Dr. Radu Minea leading the USC component.<\/li>\n<\/ul>\n<p>These prestigious NIH awards arrive as NeOnc approaches the end-of-Phase 1 milestone for NEO212, marking a pivotal point in the company\u2019s path toward Phase 2 trial initiation and potential regulatory engagement.<\/p>\n<p>\u201cSecuring $2.5 million in competitive NIH grants during one of the most uncertain federal funding periods reaffirms the scientific and clinical promise of NEO212,\u201d said Dr. Thomas Chen, CEO and Chief Medical Officer of NeOnc Technologies Holdings, Inc. \u201cAs a brain and spine oncologic surgeon for over 30 years at Keck Medical Center of USC, I have witnessed the urgent need for novel, less toxic therapies. These grants are a testament to our research team\u2019s commitment and our ability to translate academic science into meaningful treatments.\u201d<\/p>\n<p>The STTR mechanism enables collaborative development between NeOnc and leading academic institutions, with each grant structured as 40% funding to NeOnc Technologies and 60% to its USC-based research collaborators.<\/p>\n<p>This funding builds on NeOnc\u2019s growing clinical and translational momentum as the company continues to innovate across glioblastoma, leukemia, and other high-unmet-need indications.<\/p>\n<p>\n        <strong>ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.<\/strong><br \/>\n        <br \/>NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company\u2019s NEO<sup>\u2122<\/sup>\u00a0drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc\u2019s NEO100<sup>\u2122<\/sup>\u00a0and NEO212<sup>\u2122<\/sup>therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.<\/p>\n<p>For more about NeOnc and its pioneering technology, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sCxGIypbYxhj9f-a20ZsUOVN4CVuUqDo_-DM1kkzmdYmqfHtw93ZiHyBVABOd2qHShFUJesJUYWQgWvmlog_p1heS9u_0kxyjjDVSR5PvGOZD2PrEn4vFN3BQ3EbW2829A9vfsf8YoHzcb3OFyDRku7cKoJsLAr-elb64m9DsokJhXordVh4v6Ooo9DBCO00nOwQkvB4dfXivUlCJr4VYNj9kv_PMSAD6zI1jUaBv1o=\" rel=\"nofollow\" target=\"_blank\"><u>neonc.com<\/u><\/a>.<\/p>\n<p>Important Cautions Regarding Forward Looking Statements<\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cevaluating,\u201d or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.<\/p>\n<p>Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.<\/p>\n<p>The \u201cRisk Factors\u201d section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.<\/p>\n<p>We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.<\/p>\n<p>\u201cNEO100\u201d and NEO \u201c212\u201d are registered trademarks of NeOnc Technologies Holdings, Inc.<\/p>\n<p>Company Contact:<br \/><u>i<\/u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PETlI6KX-CjhEjRJ2eH5ol3LvlfGOBkuhWLKqUXk0JzKowoI8O8_ZyBBX6K2EVwW9pKeBgPXT6-gFasuj0xiEqA7OtxH-Hk0TMh7PYY7rfN3Z_66YVzfWAXbWgZ-P0hLraxBvIcH6DKVXx3QnZfiQyuTxMIRcq_T8sWlrkn-svhwnBv_oDv_UonIdJS_9lwdeN-SGEVsMOgf4d-8RFRo0efW6q29q9hHb3BDUrUAVLs=\" rel=\"nofollow\" target=\"_blank\"><u>nfo@neonc.com<\/u><\/a><\/p>\n<p>Investor Contact:<br \/>James Carbonara<br \/>Hayden IR<br \/>(646)-755-7412<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nDlrCjLm__8nJrem6D5Q5jUSToecH2SZoCym03cXsPgUxkYlGq9argeLUmnD9fQ8caf6B6qv1r7L6uZb482Uss0xXUGAwFgUATHiNC3SYmFAQsN7DF2-sFOoMliM3eoUwNHLeuRLY-yIMF_T97qlV_t7uzhIzlfC_zoZdQ4gGO1w_MJRmN414MR5g_us527fwR3_SL7S9_AdHJdeKmWH6ezBWXp_1CJMiltplAPKZJ12XYkv51uiyPcF8vdrY5Uy4SOb6llzvW3h0lvqemHB_r-cNrMf1r0io4tc4kUWJJoVcAsInIu-fGyt09j3IFtEH6O3yLSKsYmfxzQHmCwRV1lvrZ4_yNNtUKydvf51QuYnzRZrYvI1aAlbCitW-WK6H_JVklMlYBVUuzsl5i41DtDMtu-qInWQNVGFS3MqN49rpBAy4QU9k0s1QSnJKNwZ8Sm1A7lE45_4aZb5TKG58EMYE_9_9yOx9jNP8-7HcYeBFymrx9vujOapEZQHUfhT\" rel=\"nofollow\" target=\"_blank\"><u>James@haydenir.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmY4ZTZlMjUtYzM4NC00M2RhLWE5N2MtYmFkYTNjYTU4ZTUyLTEyNjgzODctMjAyNS0wOC0wNy1lbg==\/tiny\/NeOnc-Technologies-Holdings-In.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi\u2013Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company\u2019s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOnc\u2019s Principal Investigator (PI), with Dr. Axel H. Sch\u00f6nthal leading the academic research effort at USC\u2019s Glioma Research Group. $2.1 Million Phase 2 STTR Grant (2R42CA246902-02): Focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872707","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi\u2013Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company\u2019s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOnc\u2019s Principal Investigator (PI), with Dr. Axel H. Sch\u00f6nthal leading the academic research effort at USC\u2019s Glioma Research Group. $2.1 Million Phase 2 STTR Grant (2R42CA246902-02): Focused on &hellip; Continue reading &quot;NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T13:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia\",\"datePublished\":\"2025-08-07T13:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/\"},\"wordCount\":761,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/\",\"name\":\"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\",\"datePublished\":\"2025-08-07T13:05:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk","og_description":"CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi\u2013Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company\u2019s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOnc\u2019s Principal Investigator (PI), with Dr. Axel H. Sch\u00f6nthal leading the academic research effort at USC\u2019s Glioma Research Group. $2.1 Million Phase 2 STTR Grant (2R42CA246902-02): Focused on &hellip; Continue reading \"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T13:05:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia","datePublished":"2025-08-07T13:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/"},"wordCount":761,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/","name":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=","datePublished":"2025-08-07T13:05:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzQ5NyM3MDg0OTIzIzIyNTY4Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872707"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872707\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}